Sociodemographic factors, biomarkers and comorbidities associated with post-acute COVID-19 sequelae in UK Biobank.

Publication date: Jul 30, 2025

Long-term sequelae of COVID-19 remain critical public health concerns, with limited therapeutic options available. We conducted two case-control studies among COVID-19 infected individuals in the UK Biobank to explore the association of sociodemographic factors, clinical biomarkers, and comorbidities with the risk of two key phenotypes: Long COVID (LC, defined by patient self-report symptoms) and post-acute complications of SARS-CoV-2 infection (PACS, defined by clinical diagnosis), separately. Our study included 8,668 participants in the LC cohort (32% classified as cases) and 108,407 in the PACS cohort (with 2% being cases). Findings showed that age and sex were associated with both LC and PACS but in opposite directions. Additionally, obesity, socioeconomic deprivation, elevated C-reactive protein, triglyceride, vitamin D, HbA1c, cystatin C, urate, and alanine aminotransferase, and decreased HDL cholesterol and IGF-1, as well as CKD and COPD, were associated with LC. Most of these factors were also significant for PACS, except for alanine aminotransferase and vitamin D. These findings have potential mechanistic implications for the distinction between LC and PACS and can guide clinical implementation of identifying high-risk groups for targeted vaccination or other public health mitigation strategies.

Open Access PDF

Concepts Keywords
Biobank Adult
Obesity Aged
Triglyceride Biological Specimen Banks
Vaccination Biomarkers
Biomarkers
Case-Control Studies
Comorbidity
COVID-19
Female
Humans
Male
Middle Aged
Post-Acute COVID-19 Syndrome
Risk Factors
SARS-CoV-2
Sociodemographic Factors
UK Biobank
United Kingdom

Semantics

Type Source Name
drug DRUGBANK Mecasermin
drug DRUGBANK Uric Acid
drug DRUGBANK Vitamin D
disease MESH obesity
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long COVID
disease MESH sequelae
disease MESH COVID-19
disease MESH COPD
drug DRUGBANK L-Alanine
drug DRUGBANK Factor IX Complex (Human)
disease MESH infection
disease MESH myocardial infarction
disease MESH pulmonary embolism
disease MESH anxiety
disease MESH depression
disease MESH asthma
pathway KEGG Asthma
disease IDO immunosuppression
drug DRUGBANK Von Willebrand Factor Human
drug DRUGBANK Hydroxyethyl Starch
drug DRUGBANK Imidacloprid
drug DRUGBANK Cholesterol
disease MESH Comorbidity

Original Article

(Visited 2 times, 1 visits today)